Plasma FGF23 levels increase rapidly after acute kidney injury

[1]  Herbert Chase,et al.  FGF-23 levels in patients with AKI and risk of adverse outcomes. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[2]  Huiliang Xie,et al.  Fibroblast growth factor 23 and Inflammation in CKD. , 2012, American Society of Nephrology. Clinical Journal.

[3]  Hai Qing,et al.  Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  H Lester Kirchner,et al.  Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. , 2012, Kidney international.

[5]  Jason R. Stubbs,et al.  Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  A. Kapsoritakis,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity , 2012, Journal of Gastroenterology.

[7]  H. Jüppner,et al.  Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  Huiliang Xie,et al.  Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[9]  E. Farrow,et al.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice , 2011, Proceedings of the National Academy of Sciences.

[10]  E. Farrow,et al.  Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. , 2011, Bone.

[11]  A. Cheung,et al.  FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. , 2011, Journal of the American Society of Nephrology : JASN.

[12]  W. Sellers,et al.  FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  V. Shalhoub,et al.  Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. , 2011, Kidney international.

[14]  Leah R. Padgett,et al.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. , 2011, The Journal of clinical endocrinology and metabolism.

[15]  Shuang Huang,et al.  Heme oxygenase-1 induction contributes to renoprotection by G-CSF during rhabdomyolysis-associated acute kidney injury. , 2011, American journal of physiology. Renal physiology.

[16]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[17]  Chi-yuan Hsu,et al.  FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study , 2011, Annals of intensive care.

[18]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[19]  M. Wolf,et al.  Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. , 2011, Journal of the American Society of Nephrology : JASN.

[20]  S. Casier,et al.  Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. , 2011, Clinical biochemistry.

[21]  S. Harris,et al.  Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. , 2011, The Journal of endocrinology.

[22]  V. Jorgetti,et al.  FGF-23 as a predictor of renal outcome in diabetic nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[23]  G. Hampson.  Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation , 2011, Calcified Tissue International.

[24]  R. Elashoff,et al.  Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. , 2011, Kidney international.

[25]  M. Kuro-o,et al.  Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. , 2010, Kidney international.

[26]  Masaaki Inaba,et al.  Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  J. Silver,et al.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. , 2010, American journal of physiology. Renal physiology.

[28]  M. Kemper,et al.  Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. , 2010, Kidney international.

[29]  R. Elashoff,et al.  The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). , 2010, The Journal of clinical endocrinology and metabolism.

[30]  O. Mäkitie,et al.  Long-Term Clinical Outcome and Carrier Phenotype in Autosomal Recessive Hypophosphatemia Caused by a Novel DMP1 Mutation , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  J. Bacchetta,et al.  The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. , 2010, The Journal of clinical endocrinology and metabolism.

[32]  D. Leaf,et al.  Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  C. Cohen,et al.  Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  M. Wolf,et al.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. , 2010, The Journal of clinical endocrinology and metabolism.

[35]  Jean-Philippe Lafrance,et al.  Acute kidney injury associates with increased long-term mortality. , 2010, Journal of the American Society of Nephrology : JASN.

[36]  C. Ronco,et al.  NGAL: a biomarker of acute kidney injury and other systemic conditions , 2010, International Urology and Nephrology.

[37]  R. Takagi,et al.  FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. , 2009, Journal of electron microscopy.

[38]  R. Pereira,et al.  Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. , 2009, Bone.

[39]  Hang Lee,et al.  Effects of hPTH(1‐34) Infusion on Circulating Serum Phosphate, 1,25‐Dihydroxyvitamin D, and FGF23 Levels in Healthy Men , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  C. Chazot,et al.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  R. Elashoff,et al.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. , 2009, The Journal of clinical endocrinology and metabolism.

[42]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[43]  Jonathan Himmelfarb,et al.  Acute kidney injury increases risk of ESRD among elderly. , 2009, Journal of the American Society of Nephrology : JASN.

[44]  G. Yancopoulos,et al.  Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. , 2008, Kidney international.

[45]  I. Heilberg,et al.  Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. , 2008, Journal of bone and mineral metabolism.

[46]  I. Heilberg,et al.  Usefulness of a quick decalcification of bone sections embedded in methyl metacrylate: an improved method for immunohistochemistry , 2008, Journal of Bone and Mineral Metabolism.

[47]  S. Takeda,et al.  Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans , 2007, Journal of Bone and Mineral Metabolism.

[48]  A. Arnold,et al.  Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. , 2007, Journal of the American Society of Nephrology : JASN.

[49]  J. Aubin,et al.  Mineralized tissue cells are a principal source of FGF23. , 2007, Bone.

[50]  I. Day.  Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome , 2007 .

[51]  T. Yamashita,et al.  Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.

[52]  Hang Lee,et al.  Regulation of C‐Terminal and Intact FGF‐23 by Dietary Phosphate in Men and Women , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  Jason R. Stubbs,et al.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. , 2006, Journal of the American Society of Nephrology : JASN.

[54]  Jonathan Himmelfarb,et al.  Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. , 2006, Journal of the American Society of Nephrology : JASN.

[55]  Joseph V Bonventre,et al.  Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. , 2005, Journal of the American Society of Nephrology : JASN.

[56]  M. Wolf,et al.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[57]  K. White,et al.  Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. , 2005, Bone.

[58]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[59]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[60]  H. Jüppner,et al.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. , 2003, Kidney international.

[61]  Hideaki Takahashi,et al.  Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[62]  D. Miao,et al.  Parathyroid hormone is essential for normal fetal bone formation. , 2002, The Journal of clinical investigation.

[63]  A. Tamori,et al.  Severely reduced production of klotho in human chronic renal failure kidney. , 2001, Biochemical and biophysical research communications.

[64]  R. Baron,et al.  Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. , 1998, Endocrinology.